Biotech News

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

Spyre Therapeutics, Inc. (SYRE)Spyre Therapeutics, Inc.Conference / presentation

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences:

Event : Citi 2026 BioPharma Back to School Conference – New York Date: Wednesday, September 9, 2026 Fireside Time: 10:00 am ET

Event: Wells Fargo 21st Annual Healthcare Conference – Boston Date: Thursday, September 10, 2026 Fireside Time: 8:00 am ET

Event: Stifel 2026 Virtual Immunology and Inflammation Forum Date: Wednesday, September 23, 2026 Fireside Time: 8:30 am ET

Members of the Spyre management team will also host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations .

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre's website at www.spyre.com.

For Investors: Eric McIntyre, Spyre Therapeutics SVP of Finance and Investor Relations [email protected]

Related news

Spyre Therapeutics, Inc.

Long-Acting Immunology Antibodies Spyre Therapeutics develops extended-half-life antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. Its strategy is to combine established immunology targets with less frequent subcutaneous dosing and, ultimately, multi-mechanism regimens. SKYLINE IBD Platform The...

Recent company news

Stock data

Close
92.68 USD
Market cap
6.01B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States